Last updated: February 25, 2026
What is NDC 00009-0012?
NDC 00009-0012 corresponds to Humulin R U-100 (insulin human, recombinant). It is a brand of rapid-acting insulin used in diabetes management.
Market Overview
Size and Value
- The global insulin market was valued at approximately $24.2 billion in 2022.
- Compound annual growth rate (CAGR) from 2023 to 2028 is estimated at 7.1%, driven by increasing diabetes prevalence and insulin adoption.
Key Players
- Eli Lilly (Humulin R, Humulin N, Humalog)
- Novo Nordisk (Novolin R, Novolog)
- Sanofi (Insuman)
- Others including biosimilar manufacturers
Treatment Landscape
- Insulin remains a cornerstone therapy for type 1 and some type 2 diabetes patients.
- Biosimilars are entering markets, influencing pricing and competitive dynamics.
- Prescriptions for insulin increased 11% from 2020 to 2022, reflecting growth in diagnosed diabetes.
Market Drivers
- Rising diabetes prevalence: 537 million adults worldwide (2021).
- Improved diagnosis and access in emerging markets.
- Healthcare policy shifts favoring basal-bolus regimens.
Pricing Analysis
Current Pricing Benchmarks
| Product |
Instance |
Approximate Price per Dose |
Price Range (USD) |
| Humulin R U-100 |
10 mL vial (100 units/mL) |
$90 |
$85–$100 |
| Humulin R U-100 |
Pen (injector) |
$120 |
$115–$130 |
| Biosimilars |
Comparable formulations |
$70–$80 |
undercut branded prices |
Note: Pricing varies based on pharmacy, insurance, and geographical region.
Price Trends (2020–2023)
- Branded insulin prices increased approximately 5% annually.
- Biosimilars entered markets in 2021, leading to a decline in prices for generic options.
- Insurance rebates and pharmacy benefits impact net prices, often lowering out-of-pocket costs for patients.
Price Projection (2023–2028)
- For originator products like Humulin R U-100: expect a compound annual increase of 2–3%, driven by manufacturing costs and regulatory factors.
- For biosimilars: prices may decline 10–15% initially, then stabilize as market shares solidify.
- Overall market prices for insulin are projected to grow at a CAGR of 5%, considering inflation and market dynamics.
Regulatory and Policy Factors
- Recent FDA approvals allow biosimilar insulin products to enter the U.S. market seamlessly.
- Price control measures in Europe and certain U.S. states aim to reduce insulin costs, potentially capping increases.
- Patent expirations for some insulin formulations are scheduled through 2024–2026, increasing biosimilar competition.
Market Entry and Competitive Impact
- Biosimilar competition is expected to reduce premiums on original formulations.
- Companies investing in insulin analogs and delivery devices may influence long-term pricing.
- Strategic partnerships with healthcare payers will impact reimbursement rates and market penetration.
Growth and Demand Forecasts
| Year |
Predicted Market Size (USD billion) |
| 2023 |
26.0 |
| 2024 |
27.9 |
| 2025 |
30.0 |
| 2026 |
32.3 |
| 2027 |
34.7 |
| 2028 |
37.3 |
Projections consider market growth driven by diabetes prevalence and biosimilar adoption.
Risks and Challenges
- Pricing pressures from biosimilars and policy initiatives.
- Patent litigation delaying biosimilar launches.
- Supply chain disruptions impacting manufacturing costs.
Summary of Key Data Points
- Insulin market: $24.2 billion (2022), projected to grow at 7.1% CAGR.
- NDC 00009-0012 (Humulin R): priced around $90 per vial.
- Biosimilars: entering at prices 20–30% below originator brands.
- Market size forecast (2023–2028): reaching approximately $37.3 billion.
Key Takeaways
- Humulin R U-100 occupies a significant niche in rapid-acting insulin.
- Biosimilar competition is gradually reducing prices and expanding access.
- Price inflation is slow, averaging 2–3% annually for maintained brand products.
- Market expansion hinges on rising diabetes rates and increasing insulin access worldwide.
- Regulatory and patent landscapes influence future pricing and market dynamics.
FAQs
How does the entry of biosimilars impact insulin prices?
Biosimilars typically enter at prices 20–30% lower than branded insulins, leading to downward pressure on market prices and potential savings for payers and patients.
What factors influence insulin pricing beyond market competition?
Regulatory costs, manufacturing expenses, patent exclusivities, insurance rebates, and government policies all impact the final retail price.
Will the price of Humulin R U-100 decrease significantly in the next five years?
While biosimilar competition may cause slight price reductions, overall price declines are limited due to manufacturing costs and regulatory factors. Prices are expected to rise modestly at 2–3% annually.
How do regional differences affect insulin prices?
Prices are higher in the U.S., mainly due to lack of regulation on drug pricing, while Europe and other regions often have price caps and negotiated discounts.
What is the future outlook for insulin market growth?
Demand will continue driven by rising diabetes incidence, with global insulin sales projected to reach $37.3 billion by 2028, despite increased biosimilar competition.
References
[1] IQVIA. (2022). Insulin Market Insights.
[2] World Health Organization. (2021). Diabetes Fact Sheet.
[3] FDA. (2022). Biosimilar Insulin Approvals.
[4] Statista. (2023). Global Insulin Market Forecast.
[5] Centers for Medicare & Medicaid Services. (2022). Drug Price Trends and Policies.
